Curon Stretta GERD Coverage Boost In 2005 Has Sales Force Salivating
This article was originally published in The Gray Sheet
Curon Medical hopes to quintuple the reimbursement-eligible patient population for its minimally-invasive Stretta gastroesophogeal reflux disease (GERD) treatment by mid-2005
You may also be interested in...
Curon Medical's five-year battle to surpass 10% of U.S. public and private insurer coverage of its Stretta GERD therapy underscores the difficulties small companies face in navigating the reimbursement process
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.